• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Miller-Rich Nancy bought $10,447 worth of shares (922 units at $11.33) (SEC Form 4)

    10/21/24 8:22:37 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALDX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Miller-Rich Nancy

    (Last) (First) (Middle)
    C/O ALDEYRA THERAPEUTICS, INC.
    131 HARTWELL AVENUE

    (Street)
    LEXINGTON MA 02421

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Aldeyra Therapeutics, Inc. [ ALDX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/03/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/03/2021 P(1) 413 A $12.81 413 D
    Common Stock 04/12/2023 P(1) 509 A $10.13 922 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person. The Reporting Person only recently become aware of these transactions.
    /s/ Nancy Miller-Rich 10/21/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALDX

    DatePrice TargetRatingAnalyst
    4/3/2024$10.00Perform → Outperform
    Oppenheimer
    4/2/2024$10.00Buy
    H.C. Wainwright
    4/27/2022$15.00Buy
    H.C. Wainwright
    12/21/2021$25.00 → $21.00Buy
    Citigroup
    12/21/2021$24.00 → $15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

      In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

      5/5/25 6:34:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

      5/5/25 4:00:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

      4/17/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clark William D

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/18/25 4:41:01 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Clark William D

      3 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/18/25 4:21:39 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Perceptive Advisors Llc sold $4,828,000 worth of shares (3,400,000 units at $1.42) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/7/25 6:43:07 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Financials

    Live finance-specific insights

    See more
    • Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

      In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort Aldeyra Believes the Dry Eye Chamber Trial Results, including No Notable Differences in Baseline Scores Across Treatment Arms, Potentially Address FDA Feedback following the Prior NDA Review New Drug Application Resubmission Is Anticipated Mid‑2025 A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be Submitted to the Planned NDA Resubmission as Supportive Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechno

      5/5/25 6:34:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Reproxalap Reproxalap is an investigational new drug candidate in development for the

      5/5/25 4:00:00 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

      Top-Line Data from Dry Eye Chamber Trial and Field Trial Expected in Q2 2025 Pending Positive Results and Discussions with the FDA, New Drug Application Resubmission Expected Mid-Year 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no manufacturing or safety issues with reproxalap were id

      4/3/25 8:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Miller-Rich Nancy bought $10,447 worth of shares (922 units at $11.33) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      10/21/24 8:22:37 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $833,867 worth of shares (177,993 units at $4.68) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/8/24 5:32:55 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perceptive Advisors Llc bought $1,934,505 worth of shares (504,272 units at $3.84) (SEC Form 4)

      4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

      4/3/24 5:22:41 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      11/14/24 4:50:29 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc. (Amendment)

      SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/14/24 4:52:01 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aldeyra Therapeutics Inc.

      SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

      2/13/24 4:58:48 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aldeyra Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00

      4/3/24 7:39:55 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00

      4/2/24 8:09:59 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Aldeyra Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00

      4/27/22 7:14:02 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

      Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the appointment of Chip Clark to the company's board of directors. "Chip possesses a wealth of experience leading innovative biotechnology companies," stated Richard H. Douglas, Ph.D., Chairman of the Board at Aldeyra Therapeutics. "We look forward to leveraging his expertise as Aldeyra continues to advance a pipeline focused on addressing significant unmet medical needs in immune-mediated and metabolic diseases." Mr. Clark has more than three decades of leadership experience in the

      4/17/25 7:00:00 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALDX
    SEC Filings

    See more
    • Aldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      5/6/25 7:01:18 AM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Aldeyra Therapeutics Inc.

      DEFA14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/25/25 4:25:44 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aldeyra Therapeutics Inc.

      DEF 14A - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

      4/25/25 4:19:43 PM ET
      $ALDX
      Biotechnology: Pharmaceutical Preparations
      Health Care